Faruqi and Faruqui, LLP Logo
Share this page

In re Lamictal Direct Purchaser Antitrust Litig., No. 12-00995 (D.N.J.)


In the Lamictal case, Faruqi & Faruqi represents a pharmaceutical wholesaler and a proposed class of direct purchasers of SmithKline Beacham’s Lamictal, prescription drugs used to treat epilepsy, bipolar disorder and other medical conditions.  The class also includes direct purchasers of generic versions of Lamictal from Teva, SmithKline’s co-defendant and alleged co-conspirator.  The complaint alleges that SmithKline entered a reverse payment patent settlement with Teva to delay launching its first filed generic to compete with  SmithKline’s $2 billion a year Lamictal Tablets.  Such an agreement violates §§ 1 and 2 of the Sherman Act.

Contact Counsel

Peter Kohn
Joseph T. Lukens
Faruqi & Faruqi, LLP
685 Third Avenue 26th Floor
New York, NY 10017
Tel: (212) 983-9330


Case Details


  • 11/12/2015

Send Information

If you have information regarding this case that you would like to make available, please click here to contact us about our investigation.